Cerus Corporation

Steritech, Inc.

Other

Hri Research, Inc.

Carus Corporation

Hri Associates, Inc.

Stephen T Isaacs

Henry Rapoport

Susan Wollowitz

Hans Peter Spielmann

George D Cimino

John E Hearst

Aileen Nerio

David Paul Hearst

Lily Lin

John W Tessman

Peter G Carroll

Lawrence Corash

Kenneth C Metchette

David P Hearst

Laurence Corash

Kenichi K Yabusaki

John Tessman

Howard B Gamper, Jr

Goerge D Cimino

Carl V Hanson

Psoralen compound compositions are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.

Compounds for the photodecontamination of pathogens in blood

A device containing a light source, a sample support and a temperature control compartment. The sample support is positioned to support multiple sample vessels for irradiation by the light source. The temperature control compartment maintains the temperature of the sample vessels within a desired range. The light source, sample support and temperature control compartment are all contained within an opaque housing.

Device and method for photoactivation

Method for photodecontamination of pathogens in blood using 5'-primary aminopsoralens

The present invention includes compositions comprising new psoralens with either a or primary amino substituent and a blood product that is suitable for in vivo use. The compositions are useful for the inactivation of pathogens in blood products such as platelets and plasma.

A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.

Psoralen compounds

Psoralen compounds are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, use of 5&prime;-primary aminoalkyl psoralens to inactivate pathogens in platelets is disclosed.

5&prime;-primary aminoalkyl psoralen compositions with platelets

Psoralen compounds are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.

Methods for photodecontamination of pathogens in blood

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.

4'-primary aminopsoralen and platelet compositions

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic add of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular compounds with primary aminoalkyl substitutions on the 4' or 5' positions of psoralen are used to inactivate pathogens in blood products such as platelets.

Method for inactivation of pathogens in platelets using 4' and 5'

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 4' and 5' primary aminoalkyl psoralens are photoactivated in platelet preparations to inactivate pathogens.

Method for the photoactivation of 4' and 5' primary aminoalkyl psoralens

Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.

Method for the photo-decontamination of pathogens in blood using

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention compemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 5'-primary amino psoralens are photoactivated in order to inactivate pathogens in biological fluids.

Growing community of inventors

Orinda, CA, United States of America

Stephen T Isaacs